Eledon Pharmaceuticals, Inc. (ELDN) vs RxSight, Inc. (RXST)

A side-by-side comparison of Eledon Pharmaceuticals, Inc. and RxSight, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ELDN vs RXST

growth of $100 · dividends reinvested · last 5y
ELDN -61.0% (-17.2%/yr)RXST -70.3% (-21.5%/yr)ELDN compounded faster over this window
0100200300400Start $10020222023202420252026$39$30
ELDN RXST

ELDN vs RXST: by the numbers

  • •RXST is the larger company ($192M vs $189M market cap).
  • •Both run net losses; ELDN's is the smaller (0.00% vs -36.80% net margin).

Metrics side by side

Valuation

MetricELDNRXST
P/S ratioN/A1.51
P/B ratio5.730.73

Profitability

MetricELDNRXST
Gross margin0.00%77.50%
Operating margin0.00%-43.20%
Net margin0.00%-36.80%
ROE-136.83%-17.83%
ROIC-74.02%-20.24%

Growth (annualized)

MetricELDNRXST
Revenue CAGR (5Y)N/A48.85%
Total return CAGR (5Y)-15.17%-19.19%

Frequently asked

How have ELDN and RXST total returns compared?
Over the past 5 years, ELDN delivered -15.17% and RXST delivered -19.19% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.